C17orf105 Inhibitors
C17orf105 inhibitors Wortmannin and LY294002, as PI3K inhibitors, can impede downstream signaling that may regulate C17orf105 activity. Rapamycin's interaction with mTOR has the potential to disrupt signaling cascades that C17orf105 may be part of, thereby altering its function. SB203580 and PD98059 target the MAP kinase pathway by inhibiting p38 MAP kinase and MEK, respectively. This can lead to changes in the phosphorylation status and activity of proteins that are part of the same signaling network as C17orf105. JNK inhibitor SP600125 and MEK1/2 inhibitor U0126 can modify stress and growth factor signaling, potentially impacting the activity of C17orf105.
The inhibitors Trichostatin A and 5-Azacytidine affect gene expression by altering chromatin structure and DNA methylation, respectively. These changes may influence the expression and functionality of proteins, including C17orf105. Brefeldin A disrupts protein transport by inhibiting the Golgi apparatus, potentially affecting the localization and function of C17orf105. Cyclosporin A's inhibition of calcineurin may impact immune signaling pathways that involve C17orf105. Thapsigargin, by blocking SERCA pumps, leads to increased cytosolic calcium levels, which could influence the activity of C17orf105 through calcium-dependent signaling mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3K, which may be involved in the signaling pathway of C17orf105. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Targets and inhibits PI3K, potentially reducing the activity of downstream proteins in the same pathway as C17orf105. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Binds to and inhibits mTOR, a kinase that could be in a pathway with C17orf105, altering its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Selectively inhibits p38 MAP kinase, which can regulate proteins in the same pathway as C17orf105. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK, possibly affecting the MAP kinase pathway and proteins associated with C17orf105. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can alter signaling pathways involving stress responses, potentially affecting C17orf105 activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
HDAC inhibitor, which can change gene expression and protein activity in pathways including C17orf105. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methylation inhibitor that can alter gene expression and thereby protein function, including C17orf105. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts protein transport by inhibiting Golgi apparatus function, potentially affecting C17orf105 localization and function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Inhibits calcineurin, which can impact signaling pathways and proteins such as C17orf105. | ||||||